Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

UNLABELLED: The aim of this study was to determine whether respiratory syncytial virus (RSV) and other viral lower respiratory tract infections (LRTI) in prematurely born infants were associated with similar effects on healthcare utilisation and related cost of care in the second compared to the first year after birth. Thirteen infants who had RSV LRTIs (RSV), 21 who had other viral LRTIs (other viral) and 25 had no viral LRTIs (no LRTI) were prospectively followed. Nasopharyngeal aspirates were collected whenever an infant had an LRTI regardless of whether it was in the hospital or in the community. Healthcare utilisation and the health-related cost of care were determined. Only the RSV group compared to the no LRTI group had higher overall respiratory costs in both year 1 (mean, £3,917 versus £24; p 

Original publication

DOI

10.1007/s00431-014-2380-9

Type

Journal article

Journal

Eur J Pediatr

Publication Date

02/2015

Volume

174

Pages

209 - 215

Keywords

Antibodies, Monoclonal, Humanized, Antiviral Agents, Cost of Illness, Cost-Benefit Analysis, Delivery of Health Care, Health Care Costs, Hospitalization, Humans, Infant, Newborn, Infant, Premature, Palivizumab, Patient Acceptance of Health Care, Prospective Studies, Respiratory Syncytial Virus Infections, Respiratory Tract Infections